welcome
GlobalData

GlobalData

Health

Health

GlycoEra secures $130m to progress IgG4-targeted protein degrader

GlobalData
Summary
Nutrition label

80% Informative

Swiss biotechnology company GlycoEra raises $ 130 m to progress IgG4-targeted protein degrader through clinical proof-of-concept.

Investment will help in developing the company’s pipeline of precision extracellular degraders for immunology and other indications.

New investors include Novo Holdings , Roche Ventures , Bristol Myers Squibb , and 5AM Ventures .

VR Score

74

Informative language

71

Neutral language

69

Article tone

formal

Language

English

Language complexity

85

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

long-living

Affiliate links

no affiliate links